StageZero Life Sciences Ltd (TSE:SZLS) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
StageZero Life Sciences Ltd., known for its groundbreaking multi-cancer diagnostic test, Aristotle, is actively working to complete the payment of audit fees necessary to file its full year 2023 financials after a delay caused by financial constraints. The company is under a Failure to File Cease Trade Order, which prohibits trading until the financials are filed and the order is revoked, but confirms that there is no undisclosed material information.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.